Efgartigimod Phase 3 Trial Launches in Graves Disease
Phase 3 VitaliThy tests efgartigimod PH20 SC in adults with Graves disease inadequately controlled on antithyroid drugs, with safety and thyroid outcomes.
Trials, guidelines and clinical evidence across Endocrinology.
Trials, guidelines and clinical evidence across Endocrinology.